<DOC>
	<DOCNO>NCT00499291</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This clinical trial study well paclitaxel albumin-stabilized nanoparticle formulation work treat patient advanced refractory solid tumor .</brief_summary>
	<brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation Treating Patients With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To develop population pharmacokinetic model paclitaxel administer paclitaxel albumin-stabilized nanoparticle formulation ( nab-paclitaxel ) large population patient advanced refractory cancer characterize inter-individual pharmacokinetic variability agent . Secondary - To explore nab-paclitaxel pharmacokinetic parameter patient metastatic prostate cancer ( castrate ) , metastatic breast cancer , advance non-small cell lung cancer incurable advanced refractory tumor amenable treatment nab-paclitaxel . - To explore association exposure total unbound paclitaxel administration nab-paclitaxel neutropenia . - To explore association CYP2C8*3 variant paclitaxel clearance . - To explore association variant CYP2C8 gene involve paclitaxel disposition include CYP3A4 , CYP3A5 , SLCO1B3 ( OATP8 ) , ABCB1 ( MDR1 ) paclitaxel pharmacokinetic parameter toxicity one course treatment . OUTLINE : This multicenter study . Patients receive paclitaxel albumin-stabilized nanoparticle formulation ( nab-paclitaxel ) IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 . Treatment may repeat study every 9 week absence disease progression unacceptable toxicity . Serial blood sampling obtain specified time point course 1 include baseline day 1 8 course 1 pharmacokinetic study . Samples also examine genotype PCR include variant genotype 2C8 , CYP3A4 , CYP3A5 , ABCB1 , ABCC2 , ABCC10 OATP1B3 gene .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients must incurable advanced refractory tumor amenable treatment paclitaxel albuminstabilized nanoparticle formulation ( nabpaclitaxel ) Per National Comprehensive Cancer Network , follow cancer site show responsive taxane therapy : Prostate cancer Breast cancer Nonsmall cell lung cancer Bladder cancer Head neck cancer Oral cancer Cervical cancer Ovarian cancer Endometrial cancer Esophageal cancer Gastric cancer Germ cell tumor Tumors unknown primary Soft tissue sarcomas Small cell lung cancer Testicular cancer Upper genitourinary tract cancer PATIENT CHARACTERISTICS : Patients must performance status 02 ECOG scale Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 9 g/dL Bilirubin ≤ institutional upper limit normal ( ULN ) ALT AST ≤ 2.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN ( bone metastasis present absence liver metastasis , alkaline phosphatase must ≤ 5 x ULN ) Creatinine ≤ 1.5 x ULN Patients must baseline sensory neuropathy ≥ grade 2 Women must pregnant breastfeed Negative blood urine pregnancy test Women childbearing potential sexually active male must agree use accepted effective method contraception PRIOR CONCURRENT THERAPY : Prior treatment allow , may include prior taxane therapy If patient prior therapy ( y ) , s/he must receive last treatment ≥ 28 day prior registration Patients must receive colony stimulate factor ( CSFs ) Previous CSFs must discontinue &gt; 14 day prior registration Patients must receive concomitant treatment follow ( prior use allow , must discontinue ≥ 28 day prior registration ) : Phenytoin Carbamazepine Barbiturates Rifampicin Phenobarbital Hypericum perforatum ( St. John 's wort ) Ketoconazole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>clear cell sarcoma kidney</keyword>
	<keyword>rhabdoid tumor kidney</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>stage III hypopharyngeal cancer</keyword>
	<keyword>stage IV hypopharyngeal cancer</keyword>
	<keyword>recurrent laryngeal cancer</keyword>
	<keyword>stage III laryngeal cancer</keyword>
	<keyword>stage IV laryngeal cancer</keyword>
	<keyword>recurrent lip oral cavity cancer</keyword>
	<keyword>stage III lip oral cavity cancer</keyword>
	<keyword>stage IV lip oral cavity cancer</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent nasopharyngeal cancer</keyword>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
	<keyword>recurrent oropharyngeal cancer</keyword>
	<keyword>stage III oropharyngeal cancer</keyword>
	<keyword>stage IV oropharyngeal cancer</keyword>
	<keyword>recurrent paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage III paranasal sinus nasal cavity cancer</keyword>
	<keyword>stage IV paranasal sinus nasal cavity cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult teratoma</keyword>
	<keyword>ovarian teratoma</keyword>
	<keyword>testicular teratoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>recurrent carcinoma unknown primary</keyword>
</DOC>